Optinose (NASDAQ:OPTN), a pharmaceutical company specializing in ENT and allergy treatments, has announced the cancellation of its Q4 and full-year 2024 earnings conference call originally scheduled for March 20, 2025. The cancellation follows the company's earlier announcement of a definitive agreement to be acquired by Paratek Pharmaceuticals.
The acquisition deal is subject to shareholder approval and other customary closing conditions. Despite the earnings call cancellation, Optinose confirms it will still report its financial results for both the three-month and twelve-month periods ended December 31, 2024, in a timely manner.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.